Can p53 help select patients with invasive bladder cancer for bladder preservation? Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Urinary Bladder Neoplasms

abstract

  • Our study suggests that the bladder may be preserved for up to 10 years in patients with tumors confined to the bladder (stage T2) who lack detectable p53 if they respond completely to neoadjuvant chemotherapy. Patients with T3 bladder tumors or T2 p53 positive tumors are best treated currently with cystectomy.

publication date

  • January 1999

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0022-5347(01)62047-0

PubMed ID

  • 10037358

Additional Document Info

start page

  • 20

end page

  • 2; discussion 22-3

volume

  • 161

number

  • 1